These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23151650)

  • 21. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
    Rossi G; Pelizzari A; Motta M; Puoti M
    Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors.
    Lin GN; Peng JW; Xiao JJ; Liu DY; Xia ZJ
    Med Oncol; 2014 Aug; 31(8):119. PubMed ID: 25023055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.
    Lee HJ; Kim DY; Keam B; Lee JH; Han SW; Oh DY; Yoon JH; Kim TY; Kim YJ; Lee KW; Kim JW; Jeong SH; Lee JS; Kim JH; Im SA
    Breast Cancer; 2014 Jul; 21(4):387-93. PubMed ID: 23073741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab.
    Hamaki T; Kami M; Kusumi E; Ueyama J; Miyakoshi S; Morinaga S; Mutou Y
    Am J Hematol; 2001 Dec; 68(4):292-4. PubMed ID: 11754421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.
    Law JK; Ho JK; Hoskins PJ; Erb SR; Steinbrecher UP; Yoshida EM
    Leuk Lymphoma; 2005 Jul; 46(7):1085-9. PubMed ID: 16019563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
    Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
    World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lamivudine therapy in acute leukemia patients who are hepatitis B surface antigen carriers.
    Yilmaz M; Dagdas S; Güler N; Aki SZ; Aköz AG; Özet G; Ayli M; Saritas U
    Hematology; 2003 Dec; 8(6):393-6. PubMed ID: 14668034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies.
    Yağci M; Ozkurt ZN; Yeğin ZA; Aki Z; Sucak GT; Haznedar R
    Hematology; 2010 Aug; 15(4):240-4. PubMed ID: 20670484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
    Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
    Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
    Cil T; Altintas A; Pasa S; Bayan K; Ozekinci T; Isikdogan A
    Leuk Lymphoma; 2008 May; 49(5):939-47. PubMed ID: 18464113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy.
    Lu S; Xu Y; Mu Q; Cao L; Chen J; Zhu Z; Lou Y; Meng H; Qian W; Tong H; Mai W; Huang J; Yu W; Zhao X; Jin J
    Leuk Lymphoma; 2015 Apr; 56(4):1027-32. PubMed ID: 25065698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.
    Zappulo E; Nicolini LA; Di Grazia C; Dominietto A; Lamparelli T; Gualandi F; Caligiuri P; Bruzzone B; Angelucci E; Viscoli C; Mikulska M
    Infection; 2019 Feb; 47(1):59-65. PubMed ID: 30232604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience.
    Oh MJ; Lee HJ
    Clin Mol Hepatol; 2013 Mar; 19(1):51-9. PubMed ID: 23593610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.
    Lee GW; Ryu MH; Lee JL; Oh S; Kim E; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Kim WK; Lee JS; Kang YK
    J Korean Med Sci; 2003 Dec; 18(6):849-54. PubMed ID: 14676442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.